NCT04663763View on ClinicalTrials.gov

Neoadjuvant Short-course Radiotherapy Followed by the Combination of Immunotherapy and Chemotherapy in Locally Advanced Rectal Cancer

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

December 1, 2020

Primary Completion Date

December 1, 2022

Study Completion Date

December 1, 2025

Conditions
Locally Advanced Rectal Cancer
Interventions
DRUG

PD-1 antibody

Sintilimab is a humanized IgG4 monoclonal antibody against the programmed death-1 (PD-1) receptor. Usage: 200mg ivgtt d1 q3w.

DRUG

Capecitabine

Usage: 1000mg/m2 d1-14 q3w

DRUG

Oxaliplatin

Usage: 130mg/m2 d1 q3w

Trial Locations (1)

571

Zhejiang Cancer Hospital, Hangzhou

All Listed Sponsors
lead

Zhejiang Cancer Hospital

OTHER